Merz Canada Announces Xeomin Listing on Ontario Drug Benefit Formulary

May 20th, 2011

MERZ Pharma Canada Inc. is pleased to announce that effective May 19th 2011, XEOMIN(R) (clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins) has been listed with Limited Use Status on the Ontario Drug Benefit formulary (ODB). More